CN115784848A - Nor-sorbosone derivative and preparation method and application thereof - Google Patents

Nor-sorbosone derivative and preparation method and application thereof Download PDF

Info

Publication number
CN115784848A
CN115784848A CN202211565817.4A CN202211565817A CN115784848A CN 115784848 A CN115784848 A CN 115784848A CN 202211565817 A CN202211565817 A CN 202211565817A CN 115784848 A CN115784848 A CN 115784848A
Authority
CN
China
Prior art keywords
derivative
molar ratio
reaction
methoxyphenylboronic acid
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211565817.4A
Other languages
Chinese (zh)
Other versions
CN115784848B (en
Inventor
杨锐
刘建川
汪明帆
雷淑鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Univeristy of Technology
Original Assignee
Chengdu Univeristy of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Univeristy of Technology filed Critical Chengdu Univeristy of Technology
Priority to CN202211565817.4A priority Critical patent/CN115784848B/en
Publication of CN115784848A publication Critical patent/CN115784848A/en
Application granted granted Critical
Publication of CN115784848B publication Critical patent/CN115784848B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the field of pharmaceutical chemistry, and discloses a norkalopanax septentrion derivative shown as a formula I, wherein R is 1 When it is methoxy, R 2 Respectively H, C2-C8 alkyl, OH, bromoethyl, p-propylphenyl and propionitrile; when R is 1 When is H, R 2 Butyl and pentyl, respectively. The preparation method of the noralopecuroide derivative has the advantages of mild reaction conditions, simple route, low toxicity of the used reagent and simple and convenient operation. The norkalopanax delavayi extract derivative has inhibitory action with different degrees on candida albicans, candida tropicalis and cryptococcus neoformans, wherein the activity of a part of compounds is close to or similar to that of a first-line antifungal drug amphotericin B, and the norkalopanax delavayi extract derivative is used as an effective component for preparing a medical and medical antifungal drugPotential for antifungal drugs.
Figure DDA0003986578870000011

Description

Nor-sorbosone derivative and preparation method and application thereof
Technical Field
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a norsorbosol derivative, a preparation method thereof and application thereof in preparing antifungal medicines.
Background
In recent years, with the increase of the number of people suffering from AIDS, malignant tumors, organ transplantation audiences and the like, the morbidity and mortality of deep fungal infection are in an increasing situation, and the situation becomes a very challenging global health problem. The fungal infection is effectively controlled thanks to the wide use of clinical antifungal drugs, but with the long-term wide use of limited types of antifungal drugs and the serious lag of the research of novel anti-infective drugs, the drug resistance problem becomes more and more non-negligible, and particularly, the drug resistance problem of first-line azole and echinocandin drugs is very prominent, so that the clinical application of the novel antifungal drugs is urgently needed.
Natural products play a very important role in drug discovery due to their chemical structure and diversity of biological functions. Noralprostadil is a biphenyl plant antitoxin, is a chemical defense substance generated by plants in the subfamily Maloideae of Rosaceae under biotic or abiotic stress, and has proved to have excellent antimicrobial activity, anti-tumor function, insecticidal function and the like. However, as a class of natural products, the derivatives also have some limitations common to natural products, such as rare content, difficult extraction, and unsatisfactory biological activity, so it is necessary to further modify the derivatives as lead compounds to obtain derivatives with stronger activity and better pharmaceutical property.
Figure BDA0003986578850000011
Nor-sorbosone derivative with general structural formula (Nor-sorbosone R) 1 ＝OMe，R 2 ＝H)
Disclosure of Invention
The invention provides a norkalopanax derivative, a preparation method and application thereof, so as to obtain a compound with high-efficiency antifungal activity.
The purpose of the invention is realized by the following technical scheme:
nor-sorbosone derivatives represented by formula I,
Figure BDA0003986578850000012
wherein R is 1 When it is methoxy, R 2 The group is selected from any one of the following groups:
Figure BDA0003986578850000013
R 1 when is H, R 2 The radicals are respectively butyl and pentyl.
The invention also aims to provide a preparation method of the norsorbosone derivative shown in the formula I, which takes the bromobenzene compound shown in the formula II and methoxyphenylboronic acid shown in the formula III as raw materials to obtain a target compound through two steps of Suzuki coupling and demethylation. The synthetic route is as follows:
Figure BDA0003986578850000021
step (1), coupling reaction: the bromobenzene compounds shown in formulas II and III and methoxyphenylboronic acid are used as raw materials, a mixed solution of 1, 4-dioxane, water =4 (volume ratio) is used as a reaction solvent under the protection of nitrogen, potassium carbonate is used as an alkali in a reaction system, and the reaction is carried out at 90 ℃ in the presence of 0.01 equivalent of palladium acetate and 0.01 equivalent of triphenylphosphine, so as to obtain the methoxybiphenyl compound shown in formula IV.
Step (2), demethylation reaction: taking a methoxyl biphenyl compound shown as a formula IV as a raw material, taking anhydrous dichloromethane as a reaction solvent, and slowly dropwise adding BBr 3 Reacting in ice bath, and quenching with precooled alkali solution to obtain the norkalopanax derivative shown in the formula I.
In the step (1), the molar ratio of the methoxyphenylboronic acid to the substituted bromobenzene is 1.2; the molar ratio of the methoxyphenylboronic acid to the potassium carbonate is 1; the molar ratio of the methoxyphenylboronic acid to the palladium acetate is 1; the molar ratio of the methoxyphenylboronic acid to the triphenylphosphine is 1; the reaction temperature is 90 ℃; after 10 hours of reaction under nitrogen protection, water was added for dilution, extraction was performed with ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and purified by silica gel column chromatography after removal of ethyl acetate to obtain intermediate iv.
In the step (2), the intermediate IV and the demethylating reagent BBr 3 The molar ratio of (1) to (4) is 1.2 to react in an ice-water bath; after the reaction is finished, slowly adding pre-cooled 3M NaOH solution to quench the reaction, adding diluted hydrochloric acid to acidify after the solution is recovered to room temperature, removing dichloromethane, extracting with ethyl acetate, washing an organic phase with saturated saline solution, drying with anhydrous sodium sulfate, removing ethyl acetate, and performing column chromatography to obtain the norkalopanax bungeana derivative.
Pharmacological experiments show that the noralopecuroxine derivative has good antifungal activity, and the activity of a part of compounds in the noralopecuroxine derivative is close to or similar to that of a first-line antifungal medicine amphotericin B. Therefore, the invention also aims to provide the application of the norsorbose derivative in preparing antifungal medicaments.
The fungi are Candida albicans, candida tropicalis and Cryptococcus neoformans.
The compound can be used alone or in combination with clinically common antifungal drugs such as azoles, polyenes, echinocandins and pyrimidines.
The beneficial effects of the invention are:
the norkalopanax derivative has the advantages of simple preparation method, easily obtained raw materials, mild reaction conditions, convenient post-treatment and large-scale enrichment. Pharmacological experiments show that the noralopecuroxine derivative has good antifungal activity and stable property, and is expected to be developed into novel antifungal medicaments.
Drawings
FIG. 1 is a general structural formula of noralopecuroxin derivatives according to the present invention;
FIG. 2 shows Compound I prepared in example 2 of the present invention 17 Nuclear magnetic resonance hydrogen spectrum of (3);
FIG. 3 shows Compound I prepared in example 2 of the present invention 17 Nuclear magnetic resonance carbon spectrum of (1).
Detailed Description
The following examples are given to illustrate specific embodiments of the present invention.
Example 1: preparation of intermediate IV
Bromobenzene, 3,4, 5-trimethoxyphenylboronic acid or 3, 4-dimethoxyphenylboronic acid, potassium carbonate, palladium acetate and triphenylphosphine are added into a round-bottom flask according to the molar ratio of 1.2;
Figure BDA0003986578850000022
TABLE 1 Synthesis of intermediate IV
Figure BDA0003986578850000031
Example 2: preparation of noralopecuroide derivative I
Dissolving the intermediate IV in dichloromethane, stirring for 3-5 min in an ice water bath, slowly dropwise adding boron tribromide into the solution, wherein the molar ratio of the dropwise added boron tribromide to the intermediate IV is 1.2-4, continuing to react for 10min after the dropwise addition is finished, and monitoring the reaction progress by thin-layer chromatography. After the reaction is finished, slowly dropwise adding a pre-cooled 3M NaOH solution to quench the reaction. And (3) returning to room temperature, dropwise adding dilute hydrochloric acid to adjust the pH value of the solution to be less than 4, performing rotary evaporation to remove dichloromethane, adding water to dilute the solution, extracting the solution with ethyl acetate for three times, combining organic phases, washing the organic phases with saturated saline solution, drying the organic phases with anhydrous sodium sulfate, performing rotary evaporation to remove the ethyl acetate, and performing silica gel column chromatography to purify the organic phases to obtain the norsorbarin derivative I.
Figure BDA0003986578850000032
TABLE 2 Synthesis of Noralosorbin derivatives
Figure BDA0003986578850000033
The structure of noralopecuroxin derivatives is characterized as follows:
nor-sorbosone (I) 1 ) White solid; the melting point is 94.5-95.1 ℃; 1 H NMR(400MHz,CD 3 OD)δ7.61(d,J＝7.8Hz,2H),7.47–7.43(m,2H),7.35–7.31(m,1H),6.82(s,1H),6.81(s,1H),3.98(s,3H). 13 C NMR(100MHz,CD 3 OD)δ148.5,145.4,141.3,133.6,132.2,128.2(2×C),126.1(3×C),107.2,102.1,55.3.
5-methoxy- [1,1' -biphenyl]-3, 4' -trisphenol (I) 2 ) A grey solid; the melting point is 149.2-150.6 ℃; 1 H NMR(400MHz,DMSO-d 6 )δ9.35(s,1H),8.84(s,1H),8.20(s,1H),7.33(d,J＝8.1Hz,2H),6.76(d,J＝8.1Hz,2H),6.59(s,1H),6.58(s,1H),3.79(s,3H). 13 C NMR(100MHz,DMSO-d 6 )δ156.8,149.1,146.5,133.6,132.0,131.4,127.6(2×C),115.9(2×C),107.2,102.1,56.3.
4 '-Ethyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 3 ) Brown solid; the melting point is 78.1-79.3 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.46(d,J＝8.1Hz,2H),7.25(d,J＝8.1Hz,2H),6.85(s,1H),6.69(s,1H),3.94(s,3H),2.69(q,J＝7.6Hz,2H),1.28(t,J＝7.6Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ147.1,144.9,143.1,139.7,133.6,131.8,128.2(2×C),126.8(2×C),107.6,101.8,56.2,28.5,15.6.
4 '-propyl-5-methoxy- [1,1' -biphenyl]-3, 4-Diols (I) 4 ) Brown-yellow solid; the melting point is 62.5-63.9 ℃; 1 H NMR(400MHz,DMSO-d 6 )δ8.93(s,1H),8.32(s,1H),7.44(d,J＝7.7Hz,2H),7.18(d,J＝7.7Hz,2H),6.68(s,2H),3.81(s,3H),2.54(t,J＝6.2Hz,2H),1.62～1.53(m,2H),0.88(t,J＝7.3Hz,3H). 13 C NMR(100MHz,DM SO-d 6 )δ149.2,146.5,140.8,138.6,134.2,131.2,129.1(2×C),126.4(2×C),107.7,102.5,56.4,37.2,24.5,14.1.
4 '-butyl-5-methoxy- [1,1' -biphenyl]-3, 4-Diols (I) 5 ) A tan solid; the melting point is 63.9-65.2 ℃; 1 H NMR(400MHz,DMSO-d 6 )δ8.92(s,1H),8.32(s,1H),7.44(d,J＝7.7Hz,2H),7.18(d,J＝7.7Hz,2H),6.68(s,2H),3.81(s,3H),2.56(t,J＝7.7Hz,2H),1.57–1.50(m,2H),1.34–1.34(m,2H),0.88(t,J＝7.4Hz,3H). 13 C NMR(100MHz,DMSO-d 6 )δ149.2,146.5,141.0,138.5,134.2,131.2,129.1(2×C),126.4(2×C),107.7,102.5,56.3,34.8,33.6,22.2,14.2.
4'- (1-propionitrile) -5-methoxy- [1,1' -biphenyl]-3, 4-Diols (I) 6 ) Yellow solid; the melting point is 104.3-105.7 ℃; 1 H NMR(400MH z,CDCl 3 )δ7.49(d,J＝7.8Hz,2H),7.27(d,J＝7.8Hz,2H),6.83(s,1H),6.68(s,1H),3.93(s,3H),2.98(t,J＝7.4Hz,2H),2.65(t,J＝7.4Hz,2H). 13 C NMR(100MHz,CDCl 3 )δ147.2,144.1,140.1,136.7,132.9,132.2,128.6(2×C),127.3(2×C),119.2,107.7,102.2,56.3,31.2,19.4.
4'- (2-bromoethyl) -5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 7 ) Light yellow solid; the melting point is 128.1-128.8 ℃; 1 H NMR(400
MHz,CDCl 3 )δ7.49(d,J＝7.6Hz,2H),7.25(d,J＝7.6Hz,2H),6.85(s,1H),6.70(s,1H),3.94(s,3
H),3.60(t,J＝7.7Hz,2H),3.20(t,J＝7.7Hz,2H). 13 C NMR(100MHz,CDCl 3 )δ147.1,144.1,139.8,
137.6,133.1,132.0,129.0(2×C),127.0(2×C),107.7,102.2,56.4,39.0,32.9.
4 '-hexyl-5-methoxy- [1,1' -biphenyl]-3, 4-Diols (I) 8 ) Brown liquid; 1 H NMR(400MHz,CDCl 3 )δ7.45(d,J＝7.7Hz,2H),7.22(d,J＝7.7Hz,2H),6.85(s,1H),6.70(s,1H),3.94(s,3H),2.64(t,J＝7.7Hz,2H),1.68–1.61(m,2H),1.39–1.31(m,6H),0.90(t,J＝6.0Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ148.3,144.7,142.4,138.9,134.2,131.8,129.5(2×C),127.5(2×C),107.6,103.4,56.2,37.2,32.9,31.0,29.0,22.6,14.1.
4 '-cyclohexyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 9 ) Light yellow solid; the melting point is 115.6-116.2 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.46(d,J＝7.8Hz,2H),7.25(d,J＝7.8Hz,2H),6.85(s,1H),6.69(s,1H),3.93(s,3H),2.55–2.51(m,1H),1.92–1.85(m,4H),1.78–1.75(m,1H),1.50–1.36(m,4H),1.32–1.23(m,1H). 13 C NMR(100MHz,CDCl 3 )δ147.0,146.9,144.0,138.6,133.6,131.8,127.2(2×C),126.7(2×C),107.6,102.2,56.2,44.2,34.5(2×C),26.9(2×C),26.2.
4 '-tert-butyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 10 ) Brown-yellow solid; the melting point is 91.9-92.8 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.49(d,J＝8.2Hz,2H),7.45(d,J＝8.2Hz,2H),6.88(s,1H),6.72(s,1H),3.94(s,3H),1.37(s,9H). 13 C NMR(100MHz,CDCl 3 )δ150.8,147.2,144.1,138.2,134.9,132.4,127.0(2×C),125.6(2×C),108.2,102.3,67.8,34.5,31.4(3×C).
4 '-isopropyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 11 ) Yellow solid; the melting point is 90.6-91.3 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.47(d,J＝8.1Hz,2H),7.28(d,J＝8.1Hz,2H),6.86(s,1H),6.70(s,1H),3.94(s,3H),3.01–2.90(m,1H),1.30(d,J＝6.9Hz,6H). 13 C NMR(100MHz,CDCl 3 )δ148.8,146.6,144.0,138.7,134.6,131.8,126.8(4×C),108.7,104.1,56.2,34.3,24.0(2×C).
4 '-pentyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 12 ) Brown liquid; 1 H NMR(400MHz,CDCl 3 )δ7.44(d,J＝8.2Hz,2H),7.22(d,J＝8.2Hz,2H),6.84(s,1H),6.69(s,1H),3.94(s,3H),2.63(t,J＝7.9Hz,2H),1.68–1.61(m,2H),1.37–1.33(m,4H),0.91(t,J＝6.7Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ147.5,144.9,141.8,138.8,135.2,131.8,128.7(2×C),126.2(2×C),107.6,103.2,56.2,36.9,32.0,31.2,23.0,13.5.
4 '-octyl-5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 13 ) A yellow brown liquid; 1 H NMR(400MHz,CDCl 3 )δ7.47(d,J＝7.7Hz,2H),7.24(d,J＝7.7Hz,2H),6.89(s,1H),6.72(s,1H),3.93(s,3H),2.66(t,J＝7.8Hz,2H),1.71–1.63(m,2H),1.43–1.16(m,10H),0.93(t,J＝6.5Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ147.2,144.2,141.8,138.4,133.6,131.9,128.8(2×C),126.7(2×C),107.7,102.3,56.3,35.6,32.0,31.6,29.6,29.4,29.3,22.7,14.2.
4'- (4-propylphenyl) -5-methoxy- [1,1' -biphenyl]3, 4-biphenol (I) 14 ) Yellow solid; the melting point is 135.3-136.2 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.64(d,J＝8.1Hz,2H),7.60(d,J＝8.1Hz,2H),7.56(d,J＝7.7Hz,2H),7.28(d,J＝7.7Hz,2H),6.92(s,1H),6.75(s,1H),3.96(s,3H),2.65(t,J＝7.6Hz,2H),1.75–1.65(m,2H),1.00(t,J＝7.4Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ147.2,144.1,141.9,139.8,139.7,138.1,133.1,132.1,128.9(2×C),127.7(2×C),127.1(2×C),126.8(2×C),107.0,103.0,56.3,37.7,24.6,13.9.
4 '-heptyl-5-methoxy- [1,1' -biphenyl]-3, 4-Diols (I) 15 ) Brown liquid; 1 H NMR(400MHz,CDCl 3 )δ7.45(d,J＝7.7Hz,2H),7.22(d,J＝7.7Hz,2H),6.85(s,1H),6.69(s,1H),3.94(s,3H),2.63(t,J＝7.7Hz,2H),1.68–1.61(m,2H),1.36～1.25(m,8H),0.89(t,J＝6.0Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ147.1,144.0,141.8,138.4,133.6,131.8,128.7(2×C),126.7(2×C),107.6,102.2,56.2,35.6,31.8,31.5,29.3,29.2,22.7,14.1.
4 '-butyl- [1,1' -biphenyl]-3, 4-Diols (I) 16 ) A gray solid; the melting point is 142.8 to 144.1 ℃; 1 H NMR(400MHz,DMSO-d 6 )δ8.96(s,1H),8.95(s,1H),7.39(d,J＝8.2Hz,2H),7.17(d,J＝8.2Hz,2H),6.99(s,1H),6.88(d,J＝8.1Hz,1H),6.78(d,J＝8.1Hz,1H),2.55(t,J＝7.7Hz,2H),1.57–1.50(m,2H),1.34–1.25(m,2H),0.88(t,J＝7.2Hz,3H). 13 C NMR(100MHz,DMSO-d 6 )δ146.0,145.4,140.8,138.3,132.0,129.1(2×C),126.2(2×C),117.8,116.4,114.2,34.8,33.6,22.2,14.2.
4 '-pentyl- [1,1' -biphenyl]-3, 4-Diols (I) 17 ) White solid; the melting point is 145.2-147.0 ℃; 1 H NMR(400MHz,CDCl 3 )δ7.43(d,J＝7.9Hz,2H),7.22(d,J＝7.9Hz,2H),7.11(d,J＝2.1Hz,1H),7.05(dd,J＝8.3,2.1Hz,1H),6.92(d,J＝8.3Hz,1H),2.63(t,J＝7.8Hz,2H),1.68–1.61(m,2H),1.39–1.32(m,4H),0.91(t,J＝6.6Hz,3H). 13 C NMR(100MHz,CDCl 3 )δ143.6,142.8,141.7,137.9,134.8,128.8(2×C),126.6(2×C),119.7,115.7,114.1,35.5,31.5,31.2,22.5,14.0.
example 3: antifungal Activity test
Dilution of Compound I by minimal Broth 1 —Ⅰ 17 Antifungal activity tests were performed with amphotericin B (AMB) as a positive control drug.
The first step is as follows: activating the strain. Transferring the strain stored at low temperature to SDA (glucose peptone agar medium) culture medium by plate-streaking method, and standing in 35 deg.C constant temperature incubator. After three days, the cells were transferred again for use.
The second step is that: preparing a test drug mother solution. Respectively weighing a certain amount of norkalopanax derivative, dissolving with DMSO to obtain solution of 10240 μ g/mL, and storing at-20 deg.C.
The third step: and preparing working bacteria liquid. Scraping the activated strain by using an inoculating loop, transferring the strain into an SDB culture solution, carrying out shaking culture at 37 ℃ for 24h to obtain turbid bacterial suspension, adjusting the absorbance of the bacterial suspension at 620nm to 0.10-0.13 by using an ultraviolet spectrophotometer, adding 100 mu L of the turbid bacterial suspension into 100mL of sterile SDB culture solution, and shaking the turbid bacterial suspension uniformly for later use.
The fourth step: and (5) manufacturing a drug sensitive plate. After the mother solution of the test drug is returned to the room temperature, 100 mu L of the mother solution is diluted by 10 times by using sterile water, 200 mu L of the mother solution is respectively added into the first row of a 96-well plate after the mother solution is uniformly blown, and other drugs are sequentially operated. Adding 100 mu L of 10% DMSO-containing sterile water into all the wells in the 2 nd to 12 th rows, taking 100 mu L of the liquid medicine in the wells in the first row into the wells in the second row, uniformly blowing, repeating the operation, sequentially diluting to the 10 th row, taking 100 mu L, and discarding. 100. Mu.L of the working medium solution was added to each of columns 1 to 11, and 100. Mu.L of the sterile SDB culture solution was added to column 12. At this time, the volume of the solution in each well of the 96-well plate is 200. Mu.L, and the solution contains 5% DMSO, and the concentrations of the test drugs in the 1 st to 10 th columns are 512, 256, 128, 64, 32, 16,8,4,2 and 1. Mu.g/mL in this order.
The fifth step: and (4) incubating. And (3) culturing the prepared drug sensitive plate at the constant temperature of 35 ℃, culturing candida for 48 hours, and culturing cryptococcus neoformans for 72 hours.
And a sixth step: and (6) recording the result. After the culture was completed, the minimum concentration of the test drug in the well clear without fungal growth was recorded as the minimum inhibitory concentration MIC by visual observation, and each experiment was repeated three times. If the MIC is less than or equal to 1 mu g/mL, the concentration is properly reduced and the test is continued.
TABLE 3 MIC (μ g/mL) of noralopecuroxin derivatives against different pathogenic fungi.
Figure BDA0003986578850000061
Figure BDA0003986578850000062
As can be seen from Table 3, most of the noralopecuroxine derivatives of the present invention exhibited moderate to excellent antibacterial activity against three tested fungi, wherein compound I 12 、I 16 And I 17 More active, especially Compound I 17 The cryptococcus neoformans has the same inhibitory activity with the positive control AMB, is expected to become a new antifungal medicine, and is worthy of further research.
While the present invention has been described in detail with reference to the embodiments, the present invention should not be construed as limited by the scope of the claims. Various modifications and changes may be made by those skilled in the art without inventive step within the scope of the appended claims.

Claims (7)

1. The structure of the noralopecuroide derivative is shown as a formula (I),
Figure FDA0003986578840000011
wherein R is 1 When it is methoxy, R 2 Any one selected from the following groups:
Figure FDA0003986578840000012
R 1 when is H, R 2 N-butyl and n-pentyl, respectively.
2. A process for the preparation of noralopecuroxine derivatives according to claim 1, characterized by the following synthetic route:
Figure FDA0003986578840000013
wherein R is 1 When it is methoxy, R 2 Respectively H, C2-C8 alkyl, OH, bromoethyl, p-propylphenyl and propionitrile; r is 1 When is H, R 2 N-butyl and n-propyl, respectively.
3. A method for producing a noralopecuroxine derivative according to claim 2, characterized by comprising:
step (1), coupling reaction: in the presence of 0.01 equivalent of palladium acetate and 0.02 equivalent of triphenylphosphine in nitrogen atmosphere, taking a mixed solution of 1, 4-dioxane, water =4 and 1 as a reaction solvent, and taking potassium carbonate as an alkali in a reaction system, wherein bromobenzene compounds shown as a formula II and a formula III and methoxyphenylboronic acid are subjected to coupling reaction to generate an intermediate IV;
step (2), demethylation reaction: using anhydrous dichloromethane as solvent, intermediate IV and demethylating reagent BBr 3 Reacting, hydrolyzing in alkaline solution to obtain the norkalopanax derivative.
4. A method for producing a noralopecuroxine derivative according to claim 3, wherein in the step (1), the molar ratio of said methoxyphenylboronic acid to bromobenzene compound is 1; the molar ratio of the methoxyphenylboronic acid to the potassium carbonate is 1; the molar ratio of the methoxyphenylboronic acid to the palladium acetate is 1; the molar ratio of the methoxyphenylboronic acid to the triphenylphosphine is 1; the coupling reaction temperature is 90 ℃;
in the step (2), the intermediate IV and the demethylating reagent BBr 3 The molar ratio of (A) to (B) is 1.2-4; the demethylation reaction is carried out in ice-water bath; the demethylation post-treatment is quenched with a pre-cooled alkaline solution.
5. A pharmaceutical composition characterized by comprising the noralopecuroxin derivative according to claim 1 as an active ingredient.
6. Use of the noralopecuropine derivative of claim 1 or the pharmaceutical composition of claim 5 for the preparation of an antifungal agent.
7. Use according to claim 6, characterized in that the fungi are Candida albicans, candida tropicalis and Cryptococcus neoformans.
CN202211565817.4A 2022-12-07 2022-12-07 Nor-Aronia melanocarpa derivatives, and preparation method and application thereof Active CN115784848B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211565817.4A CN115784848B (en) 2022-12-07 2022-12-07 Nor-Aronia melanocarpa derivatives, and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211565817.4A CN115784848B (en) 2022-12-07 2022-12-07 Nor-Aronia melanocarpa derivatives, and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN115784848A true CN115784848A (en) 2023-03-14
CN115784848B CN115784848B (en) 2024-04-30

Family

ID=85418926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211565817.4A Active CN115784848B (en) 2022-12-07 2022-12-07 Nor-Aronia melanocarpa derivatives, and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN115784848B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110183969A1 (en) * 2008-05-29 2011-07-28 Michael Birch Antifungal combination therapy
CN102860999A (en) * 2012-10-12 2013-01-09 西北大学 1-deoxidation-D-xylulose5-phosphoric acid reduction isomerization enzyme inhibitor and preparation method thereof
CN103483158A (en) * 2013-10-14 2014-01-01 武汉英纳氏药业有限公司 Diphenylethane derivatives and application thereof
CN106831365A (en) * 2016-12-27 2017-06-13 云南民族大学 A kind of hydroxymethoxy substituted biphenyl class compound and its preparation method and application
CN107501073A (en) * 2017-08-12 2017-12-22 西北大学 Primin derivative and its synthetic method and application
WO2020262996A1 (en) * 2019-06-25 2020-12-30 (주)앰틱스바이오 Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same
CN114028456A (en) * 2021-12-03 2022-02-11 四川省畜牧科学研究院 Composition for resisting heat stress of young rabbits, application of composition and method for resisting heat stress of young rabbits
WO2022050774A1 (en) * 2020-09-03 2022-03-10 경희대학교 산학협력단 Novel imidazole derivative salt having antifungal activity, and use thereof
CN114538914A (en) * 2022-03-14 2022-05-27 成都理工大学 Zinc-doped calcium phosphate ceramic microsphere with antibacterial function and preparation method thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110183969A1 (en) * 2008-05-29 2011-07-28 Michael Birch Antifungal combination therapy
CN102860999A (en) * 2012-10-12 2013-01-09 西北大学 1-deoxidation-D-xylulose5-phosphoric acid reduction isomerization enzyme inhibitor and preparation method thereof
CN103483158A (en) * 2013-10-14 2014-01-01 武汉英纳氏药业有限公司 Diphenylethane derivatives and application thereof
CN106831365A (en) * 2016-12-27 2017-06-13 云南民族大学 A kind of hydroxymethoxy substituted biphenyl class compound and its preparation method and application
CN107501073A (en) * 2017-08-12 2017-12-22 西北大学 Primin derivative and its synthetic method and application
WO2020262996A1 (en) * 2019-06-25 2020-12-30 (주)앰틱스바이오 Derivative compound introducing biphenyl group into novel aminoalkanoic acid and antifungal pharmaceutical composition comprising same
WO2022050774A1 (en) * 2020-09-03 2022-03-10 경희대학교 산학협력단 Novel imidazole derivative salt having antifungal activity, and use thereof
CN114028456A (en) * 2021-12-03 2022-02-11 四川省畜牧科学研究院 Composition for resisting heat stress of young rabbits, application of composition and method for resisting heat stress of young rabbits
CN114538914A (en) * 2022-03-14 2022-05-27 成都理工大学 Zinc-doped calcium phosphate ceramic microsphere with antibacterial function and preparation method thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CA REGISTRY, 4 March 1999 (1999-03-04), pages 1 *
HÜTTNER C，等: "Differential effect of elicitors on biphenyl and dibenzofuran formation in Sorbus aucuparia cell cultures", J AGRIC FOOD CHEM, vol. 58, no. 22, 20 October 2010 (2010-10-20), pages 11977 - 84 *
JI BK，等: "Two new biphenyls from the stems of Garcinia tetralata", NAT PROD RES, vol. 31, no. 13, 5 February 2017 (2017-02-05), pages 1544 - 1550 *
LIU JC，等: "Natural phytoalexins inspired the discovery of new biphenyls as potent antifungal agents for treatment of invasive fungal infections", EUR J MED CHEM, vol. 261, 27 September 2023 (2023-09-27), pages 115842 *
罗兰，等: "邻烯丙基苯酚对植物病原真菌抑制机理初探", 农药学学报, no. 03, 30 September 2006 (2006-09-30), pages 279 - 282 *

Also Published As

Publication number Publication date
CN115784848B (en) 2024-04-30

Similar Documents

Publication Publication Date Title
CN103214532B (en) Avermectin B2a/2bAmido derivative, derivative salt and avermectin B2a/2bThe Preparation method and use of amido derivative salt
US20090257984A1 (en) Antifungal compositions containing the endophyte fungus alternaria alternata and or its metabolites, as antagonist agents of plasmopara viticola
US4342751A (en) Majusculamide C
KR100720776B1 (en) Rice Blast Control Agents
CN110183429A (en) 4-(N- methyl containing dithiocarbamate) amino piperidine myricetin derivative, preparation method and the usage
CN113831246A (en) Aromatic ring-containing olefine acid ester compound and preparation and application thereof
CN104860909B (en) The antibacterial activity application of griseofulvin derivative, griseofulvin and its derivative
CN110818708B (en) Compound containing fused heterocyclic structure, preparation method and application thereof, and bactericide
Tanvir et al. Endophytic actinomycetes in the biosynthesis of bioactive metabolites: chemical diversity and the role of medicinal plants
CN109467582A (en) One kind being based on avermectin B2Emamectin-benzoate synthetic method and application
CN115784848A (en) Nor-sorbosone derivative and preparation method and application thereof
CN108485987A (en) Dibenzo oxepane ketone compounds and its preparation method and application
CN114796184B (en) Compound containing semi-rigid acylhydrazone ligand, and preparation method and application thereof
CN116462652A (en) Alpha-mangostin derivative and preparation method and application thereof
CN101274885A (en) Anthraquinone coumpound for inhibitating plant pathogenic fungi
CN103664844A (en) N-(2-phenoxy benzene) furoylamide compounds and preparation method and bactericidal activity thereof
KR101671325B1 (en) Novel cyclic depsipeptide-based compound, separation method thereof, and antibacterial pharmaceutical composition containing the same as an active ingredient
CN107556296B (en) 2-hydroxy-3-azacyclo chromone compound, synthetic method thereof and application thereof in antifungal drugs
CN106467528B (en) A kind of chloro different coumarin derivative and the preparation method and application thereof
CN110885313B (en) Antibacterial active tetraphenylpyrazole compound and preparation method and application thereof
CN103319430A (en) Pinane-based isoxazoline compound as well as synthesis method and application thereof
CN107400108A (en) A kind of bicoumarin derivative and preparation method and application
EP0067212A4 (en) Para-anisole-containing biocide and methods for its isolation and use.
CN117837600A (en) Application of Iheyamine A compound in preventing and treating agricultural pathogenic bacteria
CN116478032A (en) 2',3,4',5,6 '-pentahydroxy-3' -isopentenyl chalcone analogues and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant